Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials

Human Psychopharmacology

Volumn 29, Issue 5, 2014, Pages 483-491

  Oya, Kazuto ^a   Kishi, Taro ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Efficacy; Meta analysis; Minocycline; Safety; Schizophrenia; Systematic review

Indexed keywords

MINOCYCLINE; NEUROLEPTIC AGENT;

ANOREXIA; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOSS OF APPETITE; META ANALYSIS; NAUSEA; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; URINE RETENTION; XEROSTOMIA; DRUG COMBINATION;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MINOCYCLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84922705265     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2426     Document Type: Review

References (28)

1. Addington D, Addington J, Schissel B. 1990. A depression rating scale for schizophrenics. Schizophr Res 3: 247-251.
2. Andreasen NC. 1982. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39: 784-788.
3. Chaudhry IB, Hallak J, Husain N, et al. 2012. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26: 1185-1193.
4. Chouinard G, Margolese HC. 2005. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76: 247-265.
5. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
6. Fond G, Hamdani N, Kapczinski F, et al. 2014. Effectiveness and tolerance of anti-in flammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 129: 163-179.
7. Fujita Y, Ishima T, Kunitachi S, et al. 2008. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 32: 336-339.
8. Green S. 2005. Systematic reviews and meta-analysis. Singapore Med J 46: 270-273; quiz 4.
9. Green MF, Nuechterlein KH, Gold JM, et al. 2004. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56: 301-307.
10. Guy W, Bonato RR. 1970. Manual for the ECDEU assessment battery, 2nd ed. Chevy Chase, Md, National Institute of Mental Health.
11. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
12. Hashimoto K. 2010. Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 34: 1132; author reply 3-4.
13. Hashimoto K, Ishima T, Fujita Y, Zhang L. 2013. Antibiotic drug minocycline: a potential therapeutic drug for methamphetamine-related disorders. Jpn. J. Alcohol & Drug Dependence 48: 118-125.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
15. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
16. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, et al. 2014. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res 215: 540-546.
17. Kishi T, Iwata N. 2013. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 47: 1143-1149.
18. Kishi T, Matsuda Y, Nakamura H, Iwata N. 2013. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res 47: 149-154.
19. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
20. Levkovitz Y, Mendlovich S, Riwkes S, et al. 2010. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71: 138-149.
21. Liu F, Guo X, Wu R, et al. 2014. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 153: 169-176.
22. Matsuda Y, Kishi T, Iwata N. 2013. Ef ficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. J Psychiatr Res 47: 2018-2020.
23. Miyamoto S, Jarskog LF, Fleischhacker WW. 2013. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry 26: 158-165.
24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
25. Simpson GM, Lee JH, Zoubok B, Gardos G. 1979. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 64: 171-179.
26. Sommer IE, Begemann MJ, Temmerman A, Leucht S. 2012. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38: 1003-1011.
27. Weiser MB, Fodoreanu S, Chirita L, et al. 2012. A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder [abstract]. Neuropsychopharmacology 38: S314-S446.
28. Zhang L, Shirayama Y, Iyo M, Hashimoto K. 2007. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32: 2004-2010.